Globe Life (NYSE:GL) Price Target Raised to $192.00 at Keefe, Bruyette & Woods

Globe Life (NYSE:GL) had its target price lifted by equities researchers at Keefe, Bruyette & Woods from $180.00 to $192.00 in a report released on Monday,Benzinga reports. The brokerage currently has an “outperform” rating on the stock. Keefe, Bruyette & Woods’ target price points to a potential upside of 7.20% from the stock’s previous close.

GL has been the subject of a number of other research reports. Weiss Ratings raised Globe Life from a “buy (b-)” rating to a “buy (b)” rating in a report on Wednesday, May 13th. Wells Fargo & Company increased their target price on Globe Life from $172.00 to $193.00 and gave the stock an “overweight” rating in a report on Thursday. Texas Capital upgraded Globe Life to a “strong-buy” rating in a research report on Wednesday, March 18th. TD Cowen boosted their price target on Globe Life from $199.00 to $215.00 and gave the company a “buy” rating in a research note on Tuesday, June 23rd. Finally, Jefferies Financial Group upped their price target on Globe Life from $147.00 to $166.00 and gave the company a “hold” rating in a research report on Friday. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $182.10.

Globe Life Price Performance

Shares of NYSE:GL opened at $179.10 on Monday. The company has a market cap of $13.91 billion, a price-to-earnings ratio of 12.39 and a beta of 0.47. The business has a 50 day moving average price of $163.71 and a 200 day moving average price of $150.24. The company has a quick ratio of 0.07, a current ratio of 0.07 and a debt-to-equity ratio of 0.38. Globe Life has a twelve month low of $117.30 and a twelve month high of $182.32.

Globe Life (NYSE:GL) last issued its quarterly earnings results on Wednesday, April 22nd. The company reported $3.43 earnings per share for the quarter, missing analysts’ consensus estimates of $3.46 by ($0.03). The company had revenue of $1.56 billion during the quarter, compared to the consensus estimate of $1.56 billion. Globe Life had a net margin of 19.38% and a return on equity of 20.94%. Globe Life’s revenue for the quarter was up 5.3% on a year-over-year basis. During the same period last year, the company earned $3.07 earnings per share. Globe Life has set its FY 2026 guidance at 15.400-15.90 EPS. Research analysts predict that Globe Life will post 15.64 earnings per share for the current year.

Insiders Place Their Bets

In related news, CEO Frank M. Svoboda sold 20,000 shares of the stock in a transaction that occurred on Friday, May 22nd. The stock was sold at an average price of $156.68, for a total transaction of $3,133,600.00. Following the sale, the chief executive officer directly owned 54,020 shares in the company, valued at $8,463,853.60. This represents a 27.02% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Michael Clay Majors sold 34,000 shares of the firm’s stock in a transaction on Friday, April 24th. The shares were sold at an average price of $153.81, for a total value of $5,229,540.00. Following the sale, the executive vice president directly owned 53,518 shares of the company’s stock, valued at $8,231,603.58. This represents a 38.85% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 124,187 shares of company stock worth $19,529,414 over the last ninety days. 2.11% of the stock is owned by insiders.

Institutional Investors Weigh In On Globe Life

Hedge funds have recently bought and sold shares of the company. Compound Planning Inc. raised its stake in Globe Life by 4.3% during the 4th quarter. Compound Planning Inc. now owns 1,968 shares of the company’s stock worth $275,000 after buying an additional 82 shares during the period. Root Financial Partners LLC boosted its position in shares of Globe Life by 23.3% during the first quarter. Root Financial Partners LLC now owns 439 shares of the company’s stock worth $61,000 after buying an additional 83 shares during the period. Transcend Capital Advisors LLC boosted its position in Globe Life by 3.9% during the 4th quarter. Transcend Capital Advisors LLC now owns 2,265 shares of the company’s stock worth $317,000 after acquiring an additional 84 shares during the last quarter. Natural Investments LLC boosted its stake in shares of Globe Life by 2.6% during the 4th quarter. Natural Investments LLC now owns 3,452 shares of the company’s stock worth $482,000 after buying an additional 87 shares during the last quarter. Finally, Parallel Advisors LLC boosted its holdings in shares of Globe Life by 5.6% in the 4th quarter. Parallel Advisors LLC now owns 1,651 shares of the company’s stock valued at $231,000 after buying an additional 87 shares during the last quarter. 81.61% of the stock is currently owned by institutional investors and hedge funds.

Globe Life Company Profile

Globe Life, traded on the NYSE under the symbol GL, is a U.S.-based insurance holding company that underwrites and distributes a range of life and supplemental health insurance products. Through its subsidiary brands—Globe Life, American Income Life, Liberty National Life, United American Insurance Company and Family Heritage Life—it offers term life, whole life, fixed annuities and supplemental health coverage designed to meet the needs of individuals and families across various socioeconomic segments.

The company’s product suite includes low-cost, easy-to-understand life insurance policies, accidental death and dismemberment coverage, hospital indemnity plans and specified disease insurance.